Research Study: ARTESIA
Condition:
atrial fibrillation
Study Sponsor: Hamilton Health Sciences
Study Investigator: JoEllyn Moore, MD
Study Contact: Andrew Nauertz
andrew.nauertz@allina.com
612-863-1661
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation and additional risk factors for stroke.
Eligibility Criteria:

  • Permanent pacemaker or defibrillator (with or without resynchronization) or insertable cardiac monitor capable of detecting SCAF
  • At least one episode of SCAF ≥ 6 minutes in duration but no single episode > 24 hours in duration at any time prior to enrollment. Any atrial high rate episode with average > 175 beats/min will be considered as SCAF. No distinction will be made between atrial fibrillation and atrial flutter. SCAF requires electrogram confirmation (at least one episode) unless ≥ 6 hours in duration.
  • Age ≥ 55 years
  • Risk Factor(s) for Stroke:
  1. Previous stroke, TIA or systemic arterial embolism OR Age at least 75 OR Age 65-74 with at least 2 other risk factors OR Age 55-64 with at least 3 other risk factors
  2. Other risk factors are: hypertension, CHF, diabetes, vascular disease (i.e., CAD, PAD or Aortic Plaque), female

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!

data-type="email">